Cytogenetic and loss-of-heterozygosity (LOH) studies have demonstrated that deletions of the chromosome 3 short arm (3p) occur at very high frequency in all forms of lung cancer (universal loss in SCLC AND about-80% in NSCLC). These observation suggest that 3p encodes one or more tumor suppressor genes whose loss is critical to lung cancer development and progression. Data from our laboratory and others have demonstrated 4 separate, recurring homozygous deletion regions on 3p. Project 1 will investigate the role of 3p loss in lung cancer and pre-malignant lesions. A primary goal of t his project is the translation of our experimental results into clinically useful approaches. While the most sensitive diagnostic 3p reagents will come from the actual target genes, a major advance in both LOH and FISH detection will result, respectively, from the use of highly polymorphic PCR-based markers and hybridization probes closely representing the target gene regions. To accomplish this, we will precisely define the affected 3p intervals and develop additional corresponding polymorphic markers and FSH probes that will be applied to the analysis of tumors, dysplastic biopsies and sputa. Not only will these reagents provide a powerful means for detecting small 3p alterations in diagnostic sample but they will facilitate the molecular cloning of target genes through improved definition of critical regions. B working with a common set of samples, we will be able to correlate our 3p results with those of other SPORE members and inter-SPORE collaborators investigating chr 9, p53, RB, p16INK4, cyclin D1 and other chromosomal loci frequently affected in lung cancer. From these combined data, we hope to gain a comprehensive understanding of genetic changes which characterize each type of lung cancer or pre-neoplastic lesion, and to begin to address issues of prognosis and predictability. We will further characterize and conduct gene searches within two selected target regions (distal 3p21.3 and 3p12(13) that undergo recurrent homozygous deletion as well as well as perform functional assays of candidate tumor suppressor genes. This latter effort will include transfection experiments of candidate genes into lung cancer cell lines to determine their effect on growth and tumorigenesis. Lastly, we will identify the region of chromosome 3 which encodes a recently recognized inhibitor of telomerase activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058187-08S3
Application #
6506224
Study Section
Project Start
2000-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$61,783
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Farago, Anna F; Taylor, Martin S; Doebele, Robert C et al. (2018) Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol 2018:
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182

Showing the most recent 10 out of 435 publications